Showing results (811-820 of 8,120) with videos related to

Sort By:
Pageof 812
Haematologica|April 6, 2023
Stage-specific dual function: EZH2 regulates human erythropoiesis by eliciting histone and non-histone methylationMengjia Li, Donghao Liu, Fumin Xue, et al.
Haematologica|April 6, 2023
Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemiaJanina Heilmann, Simon Vieth, Anja Möricke, et al.
Haematologica|April 6, 2023
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemiaBenedetta Fiordi, Valentina Salvestrini, Gabriele Gugliotta, et al.
Haematologica|April 6, 2023
IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disordersFrido K Bruehl, Peter Mannion, Elisha Barbato, et al.
Haematologica|February 16, 2015
Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trialMarco Mielcarek, Terrence Furlong, Barry E Storer, et al.
Haematologica|February 16, 2015
The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromesMichaela Cada, Catherin I Segbefia, Robert Klaassen, et al.
Haematologica|February 16, 2015
Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitroMuna Iraqi, Jose Perdomo, Feng Yan, et al.
Haematologica|February 25, 2015
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myelomaJesus G Berdeja, Lowell L Hart, Joseph R Mace, et al.
Haematologica|April 2, 2015
β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapiesStefano Rivella
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Pageof 812